All In Biotech

Drug Trial Radar · NCT04749368

Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic Hepatitis B Virus (HBV) Infection

A Phase 2 Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of BRII-835 (VIR-2218) and BRII-179 (VBI-2601) Combination Therapy for the Treatment of Chronic Hepatitis B Virus (HBV) Infection

Last checked: Nov 20, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

91

Actual

Start

Apr 12, 2021

Primary completion

Jul 4, 2023

Study completion Jul 4, 2023

Sponsor

Lead sponsor
Brii Biosciences LimitedIndustry
Sponsor type
Industry
Collaborators
Vir Biotechnology, Inc.; VBI Vaccines Inc.
First posted
Feb 11, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label, randomized, parallel-group study to evaluate the safety and efficacy of combination treatment BRII-835 (VIR-2218) and BRII-179 (VBI-2601) in adult participants with chronic HBV infection

Conditions

  • Hepatitis B, Chronic

Interventions

  • BRII-835 (VIR-2218)Drug

    BRII-835 (VIR-2218) will be given by subcutaneous injection

  • BRII-179 (VBI-2601) with IFN-αBiological

    BRII-179 (VBI-2601) with IFN-α will be co-administered by intramuscular injection

  • BRII-179 (VBI-2601)Biological

    BRII-179 (VBI-2601) will be administered by intramuscular injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Sustained HBsAg Loss During the 48-week Follow-up Period After NRTI WithdrawalTime frame: Up to Week 96
  2. Number of Participants With Adverse Events (AE)Time frame: Up to Week 96
  3. Number of Participants With Serious Adverse Events (SAE)Time frame: Up to Week 96
  4. Number of Participants With Abnormalities in Clinical Laboratory TestsTime frame: Up to Week 96

Locations

28 sites in 6 countries. Site status is shown where the registry gives one.

  • Investigative Site 61002

    Kingswood, New South Wales, Australia

  • Investigative Site 61001

    Westmead, New South Wales, Australia

  • Investigative Site 61004

    Herston, Queensland, Australia

  • Investigative Site 88602

    Changhua, Taiwan, China

  • Investigative Site 85201

    Hong Kong, China

  • Investigative Site 85202

    Hong Kong, China

  • Investigative Site 85203

    Hong Kong, China

  • Investigative Site 88601

    Kaohsiung, Taiwan, China

  • Investigative Site 88604

    Kaohsiung, Taiwan, China

  • Investigative Site 85204

    NEW Territories, Hong Kong, China

  • Investigative Site 88603

    Taichung, Taiwan, China

  • Investigative Site 88605

    Taipei CITY, China

  • Investigative Site 64001

    Auckland, New Zealand

  • Investigative Site 64002

    Dunedin Central, Dunedin, New Zealand

  • Investigative Site 65001

    Singapore, Singapore

  • Investigative Site 65002

    Singapore, Singapore

  • Investigative Site 82004

    Busan, South Korea

  • Investigative Site 82003

    Seongnam-si, Gyeonggi-do, South Korea

  • Investigative Site 82001

    Seoul, South Korea

  • Investigative Site 82005

    Seoul, South Korea

  • Investigative Site 82002

    Seoul, South Korea

  • Investigative Site 66001

    Bangkok, Thailand

  • Investigative Site 66003

    Chiang Mai, Thailand

  • Investigative Site 66002

    Khon Kaen, Thailand

  • Investigative Site 66005

    Nonthaburi, Thailand

  • Investigative Site 66006

    Nonthaburi, Thailand

  • Investigative Site 66004

    Pathum Thani, Thailand

  • Investigative Site 66007

    Songkhla, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.